FierceBiotech21h
GSK plans to move vaccine R&D center from Rockville, Maryland, to the Boston area
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
pharmaphorum15d
GSK's malaria vaccine gets WHO okay for mass rollout
The WHO has given a green light to widespread use of ... The RTS,S/AS01 vaccine – also known as Mosquirix – will be administered to children living in sub-Saharan Africa and other regions ...
GlobalData on MSN6d
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
pharmaphorum2d
GSK, Biological E to develop polio vaccine for India
GSK has announced a 50/50 joint venture ... and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other ...
GSK to grow Massachusetts work force with move from Maryland
The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
FiercePharma6d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Medscape3d
Immunogenicity and Safety of Inactivated Quadrivalent and Trivalent Influenza Vaccines in Children 18–47 Months of Age
Fluarixâ„¢, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...